PTC Therapeutics, Inc.
PTCT
$73.46
-$1.56-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 827.11M | 1.73B | 1.78B | 1.76B | 1.77B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 827.11M | 1.73B | 1.78B | 1.76B | 1.77B |
| Cost of Revenue | 419.58M | 401.95M | 402.93M | 459.25M | 482.53M |
| Gross Profit | 407.53M | 1.33B | 1.38B | 1.31B | 1.29B |
| SG&A Expenses | 352.37M | 347.14M | 334.95M | 324.36M | 308.60M |
| Depreciation & Amortization | 32.53M | 24.74M | 18.70M | 14.20M | 13.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 894.22M | 874.15M | 856.89M | 898.12M | 904.45M |
| Operating Income | -67.11M | 856.51M | 922.26M | 866.81M | 868.31M |
| Income Before Tax | -235.67M | 696.62M | 741.00M | 666.09M | 651.41M |
| Income Tax Expenses | -48.94M | 13.98M | -10.72M | 36.91M | 56.56M |
| Earnings from Continuing Operations | -186.73 | 682.64 | 751.72 | 629.17 | 594.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -186.73M | 682.64M | 751.72M | 629.17M | 594.84M |
| EBIT | -67.11M | 856.51M | 922.26M | 866.81M | 868.31M |
| EBITDA | -20.10M | 895.32M | 954.94M | 894.86M | 895.80M |
| EPS Basic | -2.33 | 8.79 | 9.61 | 8.02 | 7.56 |
| Normalized Basic EPS | -2.00 | 5.47 | 6.99 | 6.43 | 6.38 |
| EPS Diluted | -2.34 | 7.73 | 8.55 | 6.97 | 6.50 |
| Normalized Diluted EPS | -1.98 | 4.78 | 6.30 | 5.72 | 5.67 |
| Average Basic Shares Outstanding | 319.83M | 315.43M | 311.94M | 310.39M | 308.97M |
| Average Diluted Shares Outstanding | 328.48M | 332.34M | 328.85M | 318.66M | 317.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |